Form 4: Keros Therapeutics Director Awarded Significant Equity Compensation

Keros Therapeutics Director Jean Jacques Bienaime received a grant of 5,250 restricted stock units and options to purchase 10,500 shares of common stock on June 4, 2025.

Summary

• Jean Jacques Bienaime, a Director of Keros Therapeutics, Inc. (KROS), was granted 5,250 shares of Common Stock as a Restricted Stock Unit (RSU) award on June 4, 2025.
• The RSUs were granted at a price of $0 and will fully vest on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on the Reporting Person's continued service.
• Additionally, Mr. Bienaime was granted stock options to acquire 10,500 shares of Common Stock with an exercise price of $14.82 per share on June 4, 2025.
• These stock options will vest in equal quarterly installments over the 12 months following the grant date, with full vesting by the Issuer's 2026 annual meeting of stockholders, also subject to continued service.
• Following these transactions, Mr. Bienaime beneficially owns 5,450 shares of Common Stock directly and 10,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant operational or financial news that would dramatically alter the company's outlook.

Positives

• The grant of equity awards to a director aligns their financial interests with those of the company's shareholders, encouraging long-term value creation.
• The awards demonstrate the company's commitment to retaining and incentivizing key board members.

Risks

• Vesting of both the restricted stock units and stock options is contingent upon the Reporting Person's continued service to Keros Therapeutics, Inc.

Future Outlook

The future outlook for the reporting person's equity holdings is tied to continued service, with vesting scheduled to occur by June 2026 or the company's 2026 annual meeting, and stock options expiring in June 2035.

Industry Context

The granting of restricted stock units and stock options is a common practice in the biotechnology and pharmaceutical industries for compensating directors and executives, aiming to align their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and stock options, is a standard component of director remuneration across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedules (12-month quarterly installments for options, 1-year cliff or annual meeting for RSUs) are within typical industry ranges designed to encourage retention and long-term commitment.

Stakeholder Impact

• Shareholders: The equity awards align the director's long-term interests with shareholder value creation, potentially leading to more focused governance and strategic decisions aimed at increasing stock price.

Next Steps

• Continued service by Jean Jacques Bienaime to fulfill vesting conditions for RSUs and stock options.
• Vesting of 5,250 RSUs by June 4, 2026, or the 2026 annual meeting.
• Quarterly vesting of 10,500 stock options over 12 months, fully vested by the 2026 annual meeting.

Key Dates

Recommendation

Keywords

Keros Therapeutics, KROS, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Awards, Director Compensation, Beneficial Ownership